Trial Profile
A Phase 1B Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Glofitamab (Primary) ; Cyclophosphamide; Doxorubicin; Obinutuzumab; Polatuzumab vedotin; Prednisone; Prednisone; Rituximab; Tocilizumab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 12 Dec 2023 Results assessing durability of response beyond 12 months in Glofitamab + R-CHOP-treated pts with 1L diffuse large B-cell lymphoma from the NP40126 trial, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 11 Dec 2023 Results presented in a Roche media release.
- 18 Aug 2023 Planned End Date changed from 16 Dec 2023 to 30 Oct 2024.